Literature DB >> 24252692

Protection against Vibrio vulnificus infection by active and passive immunization with the C-terminal region of the RtxA1/MARTXVv protein.

Tae Hee Lee1, Mi Hyun Kim1, Chang-Seop Lee2, Ju-Hyung Lee3, Joon Haeng Rhee4, Kyung Min Chung5.   

Abstract

Vibrio vulnificus is a foodborne pathogen that is prevalent in coastal waters worldwide. Infection with V. vulnificus causes septicemia with fatality rates exceeding 50% even with aggressive antibiotic therapy. Several vaccine studies to prevent V. vulnificus infection have been performed but have had limited success. In this study, we identified the C-terminal region (amino acids 3491 to 4701) of the V. vulnificus multifunctional autoprocessing RTX (MARTXVv or RtxA1) protein, RtxA1-C, as a promising antigen that induces protective immune responses against V. vulnificus. Vaccination of mice with recombinant RtxA1-C protein with adjuvant elicited a robust antibody response and a dramatic reduction in blood bacterial load in mice infected intraperitoneally. Vaccination resulted in significant protection against lethal challenge with V. vulnificus. Furthermore, intraperitoneal passive immunization with serum raised against the recombinant RtxA1-C protein demonstrated marked efficacy in both prophylaxis and therapy. These results suggest that active and passive immunization against the C-terminal region of the RtxA1 protein may be an effective approach in the prevention and therapy of V. vulnificus infections.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Passive immunization; RtxA1/MARTX(Vv); Therapy; Vaccine; Vibrio vulnificus

Mesh:

Substances:

Year:  2013        PMID: 24252692     DOI: 10.1016/j.vaccine.2013.11.019

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Monoclonal antibodies against Vibrio vulnificus RtxA1 elicit protective immunity through distinct mechanisms.

Authors:  Tae Hee Lee; Sun-Shin Cha; Chang-Seop Lee; Joon Haeng Rhee; Kyung Min Chung
Journal:  Infect Immun       Date:  2014-08-25       Impact factor: 3.441

Review 2.  Multifunctional-autoprocessing repeats-in-toxin (MARTX) Toxins of Vibrios.

Authors:  Karla J F Satchell
Journal:  Microbiol Spectr       Date:  2015-06

3.  Vibrio vulnificus biotype 3 multifunctional autoprocessing RTX toxin is an adenylate cyclase toxin essential for virulence in mice.

Authors:  Kevin J Ziolo; Hee-Gon Jeong; Jayme S Kwak; Shuangni Yang; Robert M Lavker; Karla J F Satchell
Journal:  Infect Immun       Date:  2014-03-10       Impact factor: 3.609

4.  Immunogenicity and protective efficacy of Vibrio vulnificus flagellin protein FlaB in a wound infection model.

Authors:  Kohei Yamazaki; Takashige Kashimoto; Yuki Hashimoto; Takehiro Kado; Shunji Ueno
Journal:  J Vet Med Sci       Date:  2017-11-15       Impact factor: 1.267

Review 5.  Vibrio vulnificus: An Environmental and Clinical Burden.

Authors:  Sing-Peng Heng; Vengadesh Letchumanan; Chuan-Yan Deng; Nurul-Syakima Ab Mutalib; Tahir M Khan; Lay-Hong Chuah; Kok-Gan Chan; Bey-Hing Goh; Priyia Pusparajah; Learn-Han Lee
Journal:  Front Microbiol       Date:  2017-05-31       Impact factor: 5.640

6.  Immunogenicity of a bivalent protein as a vaccine against Edwardsiella anguillarum and Vibrio vulnificus in Japanese eel (Anguilla japonica).

Authors:  Songlin Guo; Linlin Hu; Jianjun Feng; Peng Lin; Le He; Qingpi Yan
Journal:  Microbiologyopen       Date:  2018-11-16       Impact factor: 3.139

7.  Protective Effects of Chicken Egg Yolk Immunoglobulins (IgYs) against Vibrio vulnificus Infections.

Authors:  Ruizhao Cai; Ning Liu; Penghao Guo; Kang Liao; Mengzhi Li; Junyou Zhu; Shouyi Chen; Lei Chen; Bin Shu; Shaohai Qi
Journal:  J Immunol Res       Date:  2021-01-06       Impact factor: 4.818

8.  Distinct roles of the repeat-containing regions and effector domains of the Vibrio vulnificus multifunctional-autoprocessing repeats-in-toxin (MARTX) toxin.

Authors:  Byoung Sik Kim; Hannah E Gavin; Karla J F Satchell
Journal:  mBio       Date:  2015-03-31       Impact factor: 7.786

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.